apramycin
Phase 1- Indications
- Bacterial infections, Antibiotic-resistant bacterial infections
Company intelligence / Profile preview
Juvabis AG
Zürich, Zürich, Switzerlandjuvabis.ch ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 1
01
Overview
EBL-1003 (apramycin) completed Phase 1 clinical trials in healthy volunteers showing it was safe and well tolerated in all dose groups. The results support further clinical development of EBL-1003 in patients[6].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculesAminoglycoside antibiotics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
European Gram-Negative Anti-Bacterial Engine (ENABLE)Innovative Medicines Initiative (IMI)RISE (Research Institutes of Sweden)
Beyond the preview
Go deeper on Juvabis AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Juvabis AG.